RNAseq data from Mesenchymal stem cells treated with TCDD or 1-methyl tryptophan

Whole genome RNA-sequencing identified Nrf2, MAPK12 and IL-1a as important downstream targets of 1MT. We further demonstrate 1a1 and 1b1 activation by 1MT in IDO+ MSC following interferon-? (IFN?) activation, suggestive that 1MT-driven AHR signaling is uncoupled from IDO catalytic function. These observations support a novel paradigm by which AHR-activating compounds like 1MT can be used in cancer immunotherapy to stimulate a pro-inflammatory response, activating the body's immune system to infiltrate and eradicate tumors. Overall design: RNAseq analysis of MSCs to a common AHR ligand (TCDD) and comparisons with 1MT, to elucidate common signaling modalities.